Research Overview
A minimal tripeptide
EDG is close to the lower size limit of this peptide family. Its glycine terminus contributes no side chain, so almost all of the molecule's character comes from the two acidic residues. That makes it a natural control sequence in structure-activity work: if a reported effect depends on side-chain identity, EDG should behave differently from EDR and EDL, which differ from it only at that third position.
Airway and lung models
Published studies have applied EDG to bronchial and alveolar epithelial cell preparations and to rodent lungs, with endpoints including tissue histology, epithelial markers, and indicators of oxidative stress. Several of these experiments used inhaled irritant exposure as the challenge, and the reported outcomes are descriptive rather than mechanistic.
Mucosal research
Part of the Chonluten literature concerns gastric and intestinal mucosa, where tissue integrity and cell-turnover markers were assessed after peptide exposure in animal models. This dual airway-and-gut focus distinguishes EDG from Bronchogen, which is discussed almost entirely in a respiratory context.
Physicochemical behaviour
With two carboxylates, a free amine, and no hydrophobic surface to speak of, EDG is strongly hydrophilic and carries a net negative charge at neutral pH. It dissolves quickly and elutes early on reversed-phase columns, which can require a modified gradient if one analytical method is being used across the whole peptide series.
